This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled ...
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (NASDAQ: VCYT) are up 23% over the last week as of market close Thursday, after the company reported ...
Investor's Business Daily on MSN
This top biotech has surged. CEO explains key to Veracyte's success.
Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
VCYT is up 65.8% in a year, outperforming the industry's decline and the S&P 500 gain. VCYT Q1'26: Afirma volume about 17.2k ( 12%) rev 21%; Decipher vol about 28k ( 24%) rev 30%. VCYT lifted 2026 ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testing growth continues to exceed our expectations, ...
VCYT is set to report Q4 results on Feb. 25, with revenues projected to rise 16.9% year over year. VCYT's Decipher and Afirma test volumes are expected to drive solid core testing growth. Veracyte ...
Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership ...
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics The posters include new data regarding ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results